Turn your evidence into access
HEORaccess is a specialist health economics and outcomes research (HEOR) and market access consultancy. We help pharmaceutical, biotechnology and medical device companies show payers, HTA bodies, clinicians and patients the true value of their products.
HTA & EU JCA-compliant reviews
Systematic literature reviews scoped to PICO and built to meet HTA body and EU Joint Clinical Assessment requirements.
We support every stage of the product lifecycle
An integrated, end-to-end HEOR offer built around one evidence strategy. Use a single service, or let us carry the evidence from early development to post-launch.
Literature reviews
HTA and EU JCA compliant systematic, targeted, scoping, umbrella, rapid and living reviews.
Adds most value from Early development to Post-launchScientific communications
Protocols, reports, abstracts, posters, manuscripts, dossiers, global value dossiers and value stories.
Adds most value from Phase II–III to Post-launchEvidence synthesis and analytics
Meta-analysis, NMA, MAIC, STC, survival analyses, utility mapping, and clinical trial and PRO analysis.
Adds most value from Phase II–III to Launch and HTAEconomic modelling
Early and submission-ready models: CEA, CUA, CMA and BIM, built de novo or adapted country by country.
Adds most value from Early development to Post-launchHTA and EU JCA submissions
Dossiers, PICO scoping and EU Joint Clinical Assessment readiness.
Adds most value from Phase II–III to Post-launchReal-world evidence
Claims, electronic health record, registry and chart review studies.
Adds most value from Pre-launch to Post-launchDigital and innovative solutions
AI tools, web-based models, dashboards, slide decks and graphical abstracts.
Adds most value from Early development to Post-launch
Bars show where each service typically adds most value.
Published, peer-reviewed work
Our team has 68 publications in journals and at congresses including ISPOR, across 12 therapeutic areas. The methods we use for clients are the ones we publish.
- 68
- Publications
- 35
- Journal articles
- 33
- Congress abstracts
- 12
- Therapeutic areas
Scientific depth, delivered faster
We combine deep scientific expertise with smart use of technology, including AI-assisted workflows, to deliver high-quality work faster without compromising rigor.
Every project is led by experienced health economists and researchers who stay closely involved from start to finish. We treat every client relationship as a long-term partnership rather than a transaction.
- Scientific integrity
- Transparency
- On-time delivery
Six reasons clients choose us
Senior-led, always
Experienced experts lead and review every project: no hand-offs to junior teams.
One-stop partner
Review, synthesis, modelling, RWE, dossiers and publications under one roof.
AI-enabled
Validated AI speeds work; humans decide.
HTA and JCA ready
Built for NICE, G-BA, HAS, CDA-AMC, US payers and EU JCA.
Agile and scalable
Flexible capacity for tight timelines and parallel deliverables.
Quality you can audit
Pre-specified methods, dual review, QC checklists and full audit trails for every output.
End-to-end EU JCA support
One joint clinical assessment now serves 27 Member States. We help you turn many national PICO requests into a single, defensible evidence package, from PICO scoping to the JCA dossier.
- Jan 2025Oncology medicines with new active substances, and ATMPs
- 2026Selected high-risk medical devices and IVDs
- Jan 2028Orphan medicinal products
- Jan 2030All new centrally authorised medicines
Specialties
The methods and deliverables our team works on every day.
- Health economics
- Outcomes research
- Evidence synthesis
- Real-world data analysis
- HTA submission
- EU JCA submission
- Early PICO simulation
- Systematic literature reviews
- Indirect treatment comparison and network meta-analysis
- Health economic modelling
- Market access
- Value communication
- Scientific writing
- HEOR writing
- PRO analysis
- Utility mapping
- Clinical trial data analysis
Questions we hear often
What is HEOR?
Health Economics and Outcomes Research (HEOR) is the discipline that measures the value of a healthcare treatment: its clinical benefit, its effect on patients' quality of life, and its cost. Payers and health technology assessment bodies use HEOR evidence to decide which treatments to fund.
What does HEORaccess do?
HEORaccess generates, shapes and communicates the evidence that supports pricing and reimbursement. Our work covers literature reviews, scientific communications, evidence synthesis and analytics, economic modelling, HTA and EU JCA submissions, real-world evidence, and digital solutions.
Who does HEORaccess work with?
We partner with pharmaceutical, biotechnology and medical device companies. We also act as a delivery partner for midsize and large consultancies that need reliable additional capacity.
How does HEORaccess use AI?
We use validated AI to speed up tasks such as literature screening and data extraction. Humans decide: experienced health economists and researchers lead every project and check the output, so the work is delivered faster without compromising rigor.
Where is HEORaccess based?
HEORaccess Pvt Ltd is headquartered in Mumbai, India, and supports evidence needs across global markets.
Patients should not be left waiting for treatments that can change their lives.
We are committed to a healthcare system where value is measured fairly and decisions are guided by sound evidence. Tell us what you are working on and we will show you how we would approach it.
